Though we identified higher IFN and urokinase production in vitro and increased NK cell activation ex vivo on Type I JAKinib withdrawal, we did not directly link these data to clinical thrombosis and cardiovascular disease. Here, IFNA1 is linked to cardiovascular disorder.